8-K: Jaguar Health Restructures Debt, Issues Warrants

Jaguar Health, Inc. exchanged royalty interests and preferred stock for pre-funded common stock purchase warrants with Iliad Research and Trading, L.P. and Streeterville Capital, LLC.

Summary

• Jaguar Health, Inc. (JAGX) entered into multiple privately negotiated exchange agreements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC on January 16, 2026.
• The company issued a total of 11,776,281 pre-funded common stock purchase warrants across six separate agreements.
• These warrants were issued in exchange for a reduction in outstanding royalty interests and the cancellation of Series L and Series M Perpetual Preferred Stock.
• Specifically, $1,187,914.07 of the October 2020 Royalty Interest with Iliad was reduced in exchange for 1,553,844 warrants.
• $850,000 of the August 2022 Royalty Interest with Streeterville was reduced in exchange for 1,111,837 warrants.
• 22 shares of Series L Preferred Stock from Iliad were exchanged for 719,424 warrants and subsequently cancelled.
• 99.3822 shares of Series L Preferred Stock from Streeterville were exchanged for 3,249,908 warrants and subsequently cancelled.
• 87.78 shares of Series M Preferred Stock from Iliad were exchanged for 2,870,503 warrants and subsequently cancelled.
• 69.44 shares of Series M Preferred Stock from Streeterville were exchanged for 2,270,765 warrants and subsequently cancelled.
• The pre-funded warrants are immediately exercisable at a nominal price of $0.001 per share, with the aggregate exercise price having been pre-funded.
• A beneficial ownership limitation of 9.99% of outstanding common stock applies to the warrant holders after exercise, which can be adjusted by the holder but not to exceed 9.99%.

Sentiment

Score: 5

Explanation: The transaction is neutral to slightly positive. While it reduces existing liabilities (royalty interests and preferred stock), it introduces significant potential dilution through the issuance of pre-funded warrants. The nominal exercise price means no new cash inflow upon exercise. It's a capital restructuring move rather than a clear positive or negative operational event.

Positives

• Reduction of outstanding royalty interests by a total of $2,037,914.07 ($1,187,914.07 from Iliad and $850,000 from Streeterville).
• Cancellation and retirement of 121.3822 shares of Series L Preferred Stock and 157.22 shares of Series M Preferred Stock, reducing future preferred dividend obligations and simplifying the capital structure.
• The conversion of existing liabilities (royalty interests and preferred stock) into potential equity can improve the company's balance sheet by reducing debt and preferred equity obligations.

Negatives

• Issuance of 11,776,281 pre-funded common stock purchase warrants will result in significant dilution for existing common stockholders upon exercise.
• The nominal exercise price of $0.001 per share means the company will receive very little additional cash upon the exercise of these warrants, as the aggregate exercise price was pre-funded.

Risks

• Potential significant dilution for existing common stockholders upon the exercise of the 11,776,281 pre-funded warrants.
• The beneficial ownership limitation of 9.99% may restrict the immediate full exercise by holders, potentially prolonging the period of uncertainty regarding future dilution.
• Failure to timely deliver Warrant Shares upon exercise could result in liquidated damages of $10 per Trading Day (increasing to $20 per Trading Day after the third day) for each $1,000 of Warrant Shares, or buy-in compensation for the holder.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future financial performance or strategic direction beyond the terms of the warrants.

Management Comments

• Lisa Conte, President and CEO, signed the Form 8-K, but no specific notable quotes or paraphrased statements from management were included in the filing text.

Industry Context

This transaction reflects a common strategy in the biotechnology or early-stage pharmaceutical industry for companies to restructure existing debt or preferred equity obligations into common stock equivalents, often to improve balance sheet health or reduce immediate cash outflows. Such exchanges are typically undertaken by companies seeking to manage their capital structure without raising new cash directly, especially when traditional financing might be challenging or dilutive at current market valuations.

Comparison to Industry Standards

• Not applicable. This filing details specific financing transactions and does not provide performance metrics or project results that can be directly compared to global industry benchmarks or specific comparable companies/projects.

Related Party Transactions

• Jaguar Health, Inc. entered into exchange agreements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC, both of whom were existing holders of the company's royalty interests and preferred stock. These are ongoing relationships with significant investors.

Stakeholder Impact

• Shareholders: Existing common shareholders face potential significant dilution from the exercise of the 11,776,281 pre-funded warrants.
• Creditors/Lenders (Iliad & Streeterville): These entities are converting a portion of their royalty interests and preferred stock into common stock warrants, indicating a shift in their investment profile from debt/preferred equity to potential common equity. This reduces the company's immediate obligations to them in the form of royalty payments or preferred dividends.

Next Steps

• Holders of the pre-funded warrants may exercise them, in whole or in part, at any time until fully exercised.
• The company is obligated to deliver Warrant Shares upon exercise and maintain a transfer agent participating in the FAST program.
• The company will make adjustments to the exercise price and number of warrant shares in case of stock dividends, splits, or other corporate actions.

Key Dates

Recommendation

The filing details a capital restructuring event where existing liabilities (royalty interests and preferred stock) are exchanged for pre-funded common stock warrants. While this reduces immediate financial obligations and simplifies the capital structure by eliminating preferred shares, it introduces substantial potential dilution for common shareholders. The nominal exercise price means no significant cash inflow from warrant exercises. This move is a balance sheet management strategy rather than an indicator of strong operational performance or significant new growth. Investors should hold to observe the impact of the dilution and the company's future operational results, as this transaction primarily addresses past financing arrangements.

Keywords

Jaguar Health, JAGX, pre-funded warrants, common stock, royalty interest, preferred stock, debt restructuring, equity financing, dilution, Iliad Research and Trading, Streeterville Capital, Series L Preferred Stock, Series M Preferred Stock, warrants